Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial — Richard B. Warren (2023) | RDL Network
Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial
Article 2023 en
Authors
RW
Richard B. Warren
AR
Adam Reich
AK
Andrzej Kaszuba
Abstract
1 min read
Imsidolimab demonstrated a rapid and sustained resolution of symptoms and pustular eruptions in patients with GPP. It was generally well tolerated, with an acceptable safety profile, and is advancing to phase III trials. These data support the targeting of IL-36 signalling with a specific antibody - imsidolimab - as a therapeutic option for this severely debilitating condition.
Shahneen Sandhu, Andrew G. Hill, Hui Gan, Michael Friedlander, Mark Voskoboynik, Paula Barlow, Amanda Townsend, Juhee Song, Y. Zhang, Li Liang, Jayesh Desai
Shahneen Sandhu, Andrew G. Hill, Hui Gan, Michael Friedlander, Mark Voskoboynik, Paula Barlow, Amanda Townsend, James Song, Yun Zhang, Zhirong Shen, Qinzhou Qi, Jayesh Desai
Joshua Richter, Thomas G. Martin, Ravi Vij, Craig E. Cole, Djordje Atanackovic, Jeffrey A. Zonder, Jonathan L. Kaufman, Joseph Mıkhael, William Bensinger, Meletios A Dimopoulos, Todd M. Zimmerman, Nikoletta Lendvai, Parameswaran Hari, Enrique M. Ocio, Cristina Gasparetto, Shaji Kumar, Corina Oprea, Éric Charpentier, Stephen A. Strickland, Jesús F. San Miguel
Thomas Thomopoulos, Anthi Bouchla, Anastasia Antoniadou, Evangelos Terpos, Maria Politou, Konstantinos Stamoulis, Eleni Koromboki, Sotirios G. Papageorgiou, Αnastasia Kotanidou, Ioannis Kalomenidis, Edison Jahaj, Sotiria Grigoropoulou, Maria Pagoni, Elisavet Grouzi, Garyphallia Poulakou, Ioannis P. Trontzas, Stavroula Labropoulou, Alexios‐Fotios A. Mentis, A Bamias, Sotirios Tsiodras, Meletios A Dimopoulos, Vasilliki Pappa
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.